CANF Can-Fite BioPharma Ltd.

NYSE canfite.com


$ 0.31 $ -0.02 (-5.79 %)    

Thursday, 20-Nov-2025 12:58:15 EST
QQQ $ 592.19 $ -19.48 (-3.18 %)
DIA $ 459.41 $ -7.30 (-1.56 %)
SPY $ 657.81 $ -15.10 (-2.25 %)
TLT $ 89.23 $ 0.24 (0.26 %)
GLD $ 374.00 $ -1.18 (-0.31 %)
$ 0.331
$ 0.32
$ 0.31 x 7,885
$ 0.31 x 621
$ 0.31 - $ 0.35
$ 0.30 - $ 2.35
12,165,198
na
nm
$ 0.98
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 can-fite-secures-brazilian-patent-for-erectile-dysfunction-drug-candidate-cf602

 Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule d...

 d-boral-capital-maintains-buy-on-can-fite-biofarma-maintains-11-price-target

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $11 price target.

 can-fite-biopharma-announces-patients-treated-with-namodenoson-reaches-overall-survival-of-9-years-with-complete-response

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small m...

 hc-wainwright--co-assumes-can-fite-biofarma-at-buy-announces-price-target-of-25

HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Can Fite Biofarma (AMEX:CANF) with a Buy rating and announces...

 d-boral-capital-maintains-buy-on-can-fite-biofarma-maintains-11-price-target

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $11 price target.

 d-boral-capital-maintains-buy-on-can-fite-biofarma-maintains-10-price-target

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $10 price target.

 can-fite-prices-5m-public-offering-of-833m-adss-at-060ads-plus-warrants-to-purchase-1667m-adss-for-up-to-10m-more

Can-Fite BioPharma Ltd.

 can-fites-piclidenoson-shows-effect-in-ucla-study-on-vascular-dementia-a-disease-with-no-approved-treatments

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary s...

 can-fite-biopharma-to-present-update-on-ongoing-phase-iia-study-in-pancreatic-cancer-during-partnering-meetings-at-2025-bio-international-convention

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary s...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION